Publicacións en colaboración con investigadores/as de Universidade de São Paulo (30)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  3. Erratum: Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (Nature (2023) 617 7962 (764-768))

    Nature

  4. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

    Nature, Vol. 617, Núm. 7962, pp. 764-768

  5. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  2. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism

    Nature Genetics, Vol. 54, Núm. 9, pp. 1320-1331

2021

  1. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy

    Forensic Science International: Genetics, Vol. 52

  2. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  3. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Association of BDNF, HTR2A, TPH1, SLC6A4, and comt polymorphisms with tdcs and escitalopram efficacy: Ancillary analysis of a double-blind, placebo-controlled trial

    Brazilian Journal of Psychiatry, Vol. 42, Núm. 2, pp. 128-135

  2. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  3. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

    Nature Communications, Vol. 10, Núm. 1

  2. Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE)

    Psychological Medicine, Vol. 49, Núm. 15, pp. 2600-2607

  3. Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths

    Forensic Science International: Genetics, Vol. 42, pp. 203-212

  4. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

    The Lancet Psychiatry, Vol. 6, Núm. 5, pp. 427-436

2018

  1. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2017

  1. A new panel of SNPs to assess thyroid carcinoma risk: A pilot study in a Brazilian admixture population

    BMC Medical Genetics, Vol. 18, Núm. 1

  2. ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy

    Basic and Clinical Pharmacology and Toxicology, Vol. 120, Núm. 5, pp. 466-474